The portfolio includes approximately 45 commercial products, four pipeline products, and 40 approved non-marketed products, including a number of generic products focused on women’s health
Dr. Reddy s will make an upfront cash payment of $90 million, as well as contingent payments of up to $15 million, inventory consideration, and credits for certain accrued channel liabilities to be determined on the closing date
Indian pharma major, Dr. Reddy's Laboratories Ltd, through its subsidiary has inked an agreement to acquire the US generic prescription product portfolio of the Australia-based, Mayne Pharma Group Limited, for consideration of about $105 .
Indian pharma major, Dr. Reddy s Laboratories Ltd, through its subsidiary has inked an agreement to acquire the US generic prescription product portfolio of the Australia-based, Mayne Pharma Group Limited, for consideration of about $105 million.
Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited, via an exchange filing.
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved